308 related articles for article (PubMed ID: 18076768)
1. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.
Sterjovski J; Churchill MJ; Ellett A; Gray LR; Roche MJ; Dunfee RL; Purcell DF; Saksena N; Wang B; Sonza S; Wesselingh SL; Karlsson I; Fenyo EM; Gabuzda D; Cunningham AL; Gorry PR
Retrovirology; 2007 Dec; 4():89. PubMed ID: 18076768
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
3. Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection.
Wade J; Sterjovski J; Gray L; Roche M; Chiavaroli L; Ellett A; Jakobsen MR; Cowley D; Pereira Cda F; Saksena N; Wang B; Purcell DF; Karlsson I; Fenyö EM; Churchill M; Gorry PR
Virology; 2010 Jan; 396(2):246-55. PubMed ID: 19913863
[TBL] [Abstract][Full Text] [Related]
4. CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity.
Sterjovski J; Churchill MJ; Roche M; Ellett A; Farrugia W; Wesselingh SL; Cunningham AL; Ramsland PA; Gorry PR
Virology; 2011 Feb; 410(2):418-28. PubMed ID: 21216423
[TBL] [Abstract][Full Text] [Related]
5. Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues.
Gray L; Sterjovski J; Ramsland PA; Churchill MJ; Gorry PR
Retrovirology; 2011 Jun; 8():42. PubMed ID: 21635737
[TBL] [Abstract][Full Text] [Related]
6. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.
Gorry PR; Taylor J; Holm GH; Mehle A; Morgan T; Cayabyab M; Farzan M; Wang H; Bell JE; Kunstman K; Moore JP; Wolinsky SM; Gabuzda D
J Virol; 2002 Jun; 76(12):6277-92. PubMed ID: 12021361
[TBL] [Abstract][Full Text] [Related]
7. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.
Gray L; Roche M; Churchill MJ; Sterjovski J; Ellett A; Poumbourios P; Sherieff S; Wang B; Saksena N; Purcell DF; Wesselingh S; Cunningham AL; Brew BJ; Gabuzda D; Gorry PR
J Virol; 2009 Jun; 83(11):5430-41. PubMed ID: 19321618
[TBL] [Abstract][Full Text] [Related]
8. Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression.
Borggren M; Repits J; Kuylenstierna C; Sterjovski J; Churchill MJ; Purcell DF; Karlsson A; Albert J; Gorry PR; Jansson M
Retrovirology; 2008 Mar; 5():28. PubMed ID: 18371209
[TBL] [Abstract][Full Text] [Related]
9. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
[TBL] [Abstract][Full Text] [Related]
10. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
11. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.
Parrish NF; Wilen CB; Banks LB; Iyer SS; Pfaff JM; Salazar-Gonzalez JF; Salazar MG; Decker JM; Parrish EH; Berg A; Hopper J; Hora B; Kumar A; Mahlokozera T; Yuan S; Coleman C; Vermeulen M; Ding H; Ochsenbauer C; Tilton JC; Permar SR; Kappes JC; Betts MR; Busch MP; Gao F; Montefiori D; Haynes BF; Shaw GM; Hahn BH; Doms RW
PLoS Pathog; 2012; 8(5):e1002686. PubMed ID: 22693444
[TBL] [Abstract][Full Text] [Related]
12. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
[TBL] [Abstract][Full Text] [Related]
13. Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5.
Salimi H; Roche M; Webb N; Gray LR; Chikere K; Sterjovski J; Ellett A; Wesselingh SL; Ramsland PA; Lee B; Churchill MJ; Gorry PR
J Leukoc Biol; 2013 Jan; 93(1):113-26. PubMed ID: 23077246
[TBL] [Abstract][Full Text] [Related]
14. Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism.
O'Connell O; Repik A; Reeves JD; Gonzalez-Perez MP; Quitadamo B; Anton ED; Duenas-Decamp M; Peters P; Lin R; Zolla-Pazner S; Corti D; Wallace A; Wang S; Kong XP; Lu S; Clapham PR
J Virol; 2013 Jan; 87(1):187-98. PubMed ID: 23055568
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 non-macrophage-tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4+ T-cells than envelopes highly adapted for macrophages.
Musich T; O'Connell O; Gonzalez-Perez MP; Derdeyn CA; Peters PJ; Clapham PR
Retrovirology; 2015 Mar; 12():25. PubMed ID: 25809903
[TBL] [Abstract][Full Text] [Related]
17. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion.
Thomas ER; Dunfee RL; Stanton J; Bogdan D; Taylor J; Kunstman K; Bell JE; Wolinsky SM; Gabuzda D
Virology; 2007 Mar; 360(1):105-19. PubMed ID: 17084877
[TBL] [Abstract][Full Text] [Related]
18. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity.
Puffer BA; Pöhlmann S; Edinger AL; Carlin D; Sanchez MD; Reitter J; Watry DD; Fox HS; Desrosiers RC; Doms RW
J Virol; 2002 Mar; 76(6):2595-605. PubMed ID: 11861825
[TBL] [Abstract][Full Text] [Related]
19. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.
Repits J; Sterjovski J; Badia-Martinez D; Mild M; Gray L; Churchill MJ; Purcell DF; Karlsson A; Albert J; Fenyö EM; Achour A; Gorry PR; Jansson M
Virology; 2008 Sep; 379(1):125-34. PubMed ID: 18672260
[TBL] [Abstract][Full Text] [Related]
20. Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.
LaBonte JA; Madani N; Sodroski J
J Virol; 2003 Jun; 77(12):6645-59. PubMed ID: 12767984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
